Maker of world's most expensive prescription drug flashes PhIII data for a potential fourth product

Three years before they became owners of the most expensive drug in the country, Amryt began its corporate life around a single therapy picked up from a small German drugmaker called Birken: Episalvan, an EMA-approved drug for partial thickness wounds. They hoped to develop it as an orphan drug for a condition called epidermolysis bullosa, where a patient’s skin becomes as fragile as butterfly wings. They put it almost immediately into a Phase III study.